Abeona Therapeutics (ABEO) stock gets a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. Read the full analysis here.

In part 1 of the exclusive interview, the Australian legend opens up about picking between cricket and medicine, the ...

Broc Sandelin talks about how his small-town farm experience helps him prepare animal science students for in-demand careers.

JAXA samples reveal that asteroid Ryugu has a complete set of nucleobases, the building blocks of DNA.

But the phrase genetic supremacist is very apt. A strange part of the strange life of Jeffrey Epstein was his obsession with ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.